Current therapeutic strategies for DCM include the use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, β-blockers, mineralocorticoid receptor antagonists, and sodium-glucose cotransporter 2 (SGLT2) inhibitors [7]. This evidence concerns the gene SLC5A2 and familial dilated cardiomyopathy.